ALPN

ANALYST NOTE: ALPINE IMMUNE SCIENCES, INC. (ALPN) DATE: 2026-06-13 CURRENT PRICE: $64.97

1. Structural Readiness

State: Context-Only / Forming

Technical Configuration:

• Conservative Entry: Not yet defined (awaiting confirmed breakout).
• Aggressive/Pre-Breakout Entry: N/A (Current price action is within the consolidation range).
• Breakout Level: Not yet fired.
• Current Price: $64.97.
• Extension: Not applicable (price is not extending above a confirmed breakout level).
• ATR Context: Current ATR is 1.1% (Sub-threshold). This indicates low volatility relative to the historical "sweet spot" (4–6%). In a forming coil, sub-threshold volatility often suggests a tightening of the range, but it also implies a lack of immediate momentum.

Interpretation:

2. Thesis Layer

Thesis Classification: TACTICAL / Setup-Led Secular Thesis: None named at this date.

This is not a name driven by a specific macro secular thesis (e.g., "AI Revolution" or "Global Aging") at this specific moment. The investment case is strictly setup-led, relying on the quality of the technical structure (the forming coil) combined with the underlying business fundamentals. We must judge this name solely on the strength of the setup and the company's operational progress, without inventing a macro narrative.

3. Business Overview

Company: Alpine Immune Sciences, Inc. Headquarters: Seattle, Washington (Founded 2007). Industry: Biotechnology / Immunology. Business Model: Clinical-stage biopharmaceutical company developing novel therapeutics for autoimmune and inflammatory diseases, as well as oncology, utilizing its "direct evolution" platform.

Key Business Activities & Evidence (as of 2026-06-13):

• Core Asset (Povetacicept): The company's flagship asset is povetacicept (ALPN-101), a next-generation dual BAFF/APRIL inhibitor with once-monthly dosing.
• *Evidence:* As of the March 2024 earnings transcript, the company reported that the majority of patients in prior studies met remission criteria (defined as UPCR < 0.5 g/g, ≥50% reduction from baseline, and stable eGFR).
• *Progress:* Management had planned to initiate the pivotal RAINIER Phase 3 study for IgA nephropathy in the second half of 2024 and the Phase 2 DENALI study for SLE. By June 2026, these studies would be in advanced execution or reporting phases.
• Pipeline Diversification:
• ALPN-202: A conditional CD28 costimulator and dual checkpoint inhibitor for cancer.
• ALPN-303: A dual B cell cytokine antagonist for B cell-mediated inflammatory conditions.
• RUBY-3: Ongoing exploration of other renal indications.
• Strategic Partnerships:
• AbbVie: Strategic collaboration for the development of ALPN-101.
• Adaptimmune: Partnership to create next-generation SPEAR T cell products.
• Financial Position:
• *Evidence:* In March 2024, management stated that cash and investments totaled $368.2 million, with an expectation to fund operations into 2026.
• *Revenue:* Collaboration revenue was $58.9 million in 2023, up from $30.1 million in 2022.
• *Capitalization:* The company closed an oversubscribed $150 million equity offering in early 2024 to accelerate development.
• *Current Financials (2026):* Forward consensus EPS for FY1 is -2.255 and FY2 is -2.15, indicating the company remains in a pre-profit growth phase with significant R&D burn.

4. Archetype and Conviction

Archetype: Growth Leader Fit: The company fits the "Growth Leader" archetype due to its focus on high-potential clinical assets (povetacicept) in large markets (IgA nephropathy, SLE) and its strategic partnerships. The business model relies on the successful execution of clinical trials to unlock value, rather than current profitability.

Valuation & Financial Context:

• Financial Spine: The forward consensus EPS remains negative (-2.255 for FY1, -2.15 for FY2). This confirms the company is in a capital-intensive growth phase.
• Conviction Stack:
• *Thesis Strength:* Low (No named secular thesis; purely tactical).
• *Evidence Quality:* Moderate. The evidence base is robust regarding the *plan* (2024 transcripts) and *partnerships*, but the 2026-specific clinical data (post-RAINIER initiation) is not explicitly detailed in the provided evidence block, creating a reliance on the assumption that the 2024 plans executed as stated.
• *Rerating Potential:* High, contingent on the successful readout of the RAINIER or DENALI studies, which would be the catalyst to move from "Forming" to "Confirmed."

5. Invalidations, Strengtheners, and Gaps

What Would Invalidate:

• Fundamental: Failure of the RAINIER or DENALI trials to meet primary endpoints, or a significant cash burn rate that threatens the "funding into 2026" guidance (though the 2024 cash position was strong).

What Would Strengthen:

• Technical: A confirmed breakout above the resistance level of the forming coil, accompanied by an increase in ATR (moving into the 4–6% sweet spot).
• Fundamental: Positive top-line data from the RAINIER (Phase 3) or DENALI (Phase 2) studies, or an expansion of the collaboration with AbbVie or Adaptimmune.

Evidence Gaps:

• 2026 Clinical Data: The provided evidence block contains specific quotes from March 2024 regarding *plans* to initiate studies. There is no explicit evidence in the provided text confirming the *results* or *status* of the RAINIER or DENALI studies as of June 2026. We do not know if the trials have completed, are ongoing, or if data has been released.
• Current Cash Position: The 2024 cash balance ($368.2M) is historical. There is no explicit evidence of the cash balance as of June 2026, though the 2024 guidance suggested sufficiency through 2026.
• 2026 Revenue: No specific revenue figures for 2025 or 2026 are provided, only the 2023 collaboration revenue.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key risks: Clinical trial failure in RAINIER or DENALI; Cash burn exceeding 2024 projections; Sub-threshold volatility (1.1% ATR) indicating lack of immediate market momentum; Negative forward EPS (-2.255 FY1). Sizing hint: Position size should be conservative given the "Forming" status and lack of confirmed clinical data for 2026; treat as a satellite holding pending breakout confirmation. Expected path: Price consolidates within the forming range; a catalyst (clinical data readout) triggers a breakout above resistance; volatility (ATR) expands as the market prices in binary clinical outcomes. Expected horizon: 3 to 6 months for a potential breakout or invalidation event.